(Q44386864)

2 December 2017

title

Position paper on the therapeutic use of rituximab in CD20-positive diffuse large B-cell non-Hodgkin's lymphoma (English)

1 reference

2 December 2017

1 reference

1 reference

2

David Linch

1 reference

2 December 2017

Ruth Pettengell

1

1 reference

2 December 2017

Haemato-Oncology Task Force of the British Committee for Standards in Haematology

series ordinal

3

1 reference

2 December 2017

language of work or name

English

0 references

publication date

1 April 2003

1 reference

British Journal of Haematology

2 December 2017

published in

1 reference

2 December 2017

volume

121

1 reference

2 December 2017

issue

1

1 reference

2 December 2017

page(s)

44-48

1 reference

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

2 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04274.X

Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04274.X

Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04274.X

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04274.X

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04274.X

10.1046/J.1365-2141.2003.04274.X

21 January 2018

Identifiers

DOI

1 reference

2 December 2017

1 reference